Novo Nordisk to boost US diabetes sales force by 60%

Share this article:
Danish drugmaker Novo Nordisk announced plans to boost the size of its US diabetes care sales force by 60%, or 700 reps, before mid-2007. Novo Nordisk controls approximately 40% of the US insulin market, which has grown increasingly competitive over the past two years following the launches of Lilly and Amylin’s GLP-1 inhibitor Byetta, Pfizer’s Exubera inhaled insulin and Merck’s DPP-4 inhibitor Januvia. Novo Nordisk said the goal of its field force expansion is to further support its currently marketed insulin analogs—Levemir, NovoLog Mix 70/30 and NovoLog—and gear up for the planned 2009 launch of its Liraglutide diabetes treatment. Analysts said the Novo sales force increase is a defensive move to help the company compete with Januvia, Exubera and Novartis’ yet-to-be approved Galvus. Poul la Cour, an analyst with Carnegie Bank, told United Press International that other companies won’t raise their sales force levels as a response. “That’s because their competitors…already have more sales reps than Novo. Eli Lilly might increase to support Byetta…But so far, that launch has been incredible, so they'll only increase if there's a slow-down.”
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.